Aktis Oncology Inc. (NASDAQ: AKTS) appointed Glenn Gormley, MD, PhD, as an independent director to its board and co-chair of the company's newly established Science and Technology Committee.

Gormley brings over 30 years of biopharmaceutical leadership experience across research and development, executive leadership, and board service. He most recently served as Senior Executive Officer and Global Head of Research and Development at Daiichi Sankyo Co., Ltd., and as Executive Chairman and President of Daiichi Sankyo, Inc. In these roles, he led global R&D strategy and oversaw the development of a broad pipeline, including the build-out of Daiichi Sankyo's antibody drug conjugate platform.

Prior to Daiichi Sankyo, Gormley held senior leadership positions at AstraZeneca as Chief Medical Officer and at Novartis as Global Head of Clinical Development and Medical Affairs. He also held senior clinical development roles at Merck. Gormley holds an MD and PhD from the University of Chicago and completed training at UCLA and New York University, leading to board certification in pediatrics and pediatric endocrinology.

"Glenn brings deep expertise in global biopharmaceutical leadership and oncology innovation, having guided several blockbuster medicines to approval," said Matthew Roden, PhD, President and Chief Executive Officer of Aktis Oncology.

Concurrent with Gormley's appointment, current board members Helen Kim and Oleg Nodelman plan to step down from Aktis' board, effective May 20, 2026.

Aktis Oncology is a clinical-stage oncology company focused on expanding targeted radiopharmaceuticals to large patient populations. The company has developed a proprietary miniprotein radioconjugate platform to deliver radioisotopes to targeted tumors.